AGIO Agios provides update on phase 2 trial of tebapivat in sickle cell disease Agios Pharmaceuticals - will not advance tebapivat in sickle
AGIO Agios provides update on phase 2 trial of tebapivat in sickle cell disease Agios Pharmaceuticals - will not advance tebapivat in sickle cell disease - Primary endpoint achieved by up to 47.1% in tebapivat arms; 33.3% in placebo Arm - Tebapivat safety consistent with prior sickle cell disease trials - FDA priority review for mitapivat in sickle cell disease; pdufa date November 1, 2026
Story updates
11:00:59 AM UTC
SquawkNews
AGIO Agios provides update on phase 2 trial of tebapivat in sickle cell disease Agios Pharmaceuticals - will not advance tebapivat in sickle cell disease - Primary endpoint achieved by up to 47.1% in tebapivat arms; 33.3% in placebo Arm - Tebapivat safety consistent with prior sickle cell disease tr
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.